Back to Journals » Drug Design, Development and Therapy » Volume 8

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

Authors de Leeuw E

Received 20 May 2014

Accepted for publication 10 June 2014

Published 8 August 2014 Volume 2014:8 Pages 1061—1064

DOI https://doi.org/10.2147/DDDT.S68020

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Erik PH de Leeuw

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

Objective: To test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii.
Methods: Susceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and this compound was assessed.
Results: Small molecule Lipid II inhibitor BAS00127538 potently acts against A. baumannii and acts synergistically with colistin.
Conclusion: For the first time, a compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii. The synergy with colistin warrants further lead development of BAS00127538.

Keywords: Lipid II, Acinetobacter baumannii, drug development

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]